The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study

SummaryBackground & aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syn...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical nutrition ESPEN 2019-10, Vol.33, p.148-153
Hauptverfasser: Akita, Hirofumi, Takahashi, Hidenori, Asukai, Kei, Tomokuni, Akira, Wada, Hiroshi, Marukawa, Satoko, Yamasaki, Tomoyuki, Yanagimoto, Yoshitomo, Takahashi, Yusuke, Sugimura, Keijiro, Yamamoto, Kazuyoshi, Nishimura, Junichi, Yasui, Masayoshi, Omori, Takeshi, Miyata, Hiroshi, Ochi, Ayami, Kagawa, Ayano, Soh, Yuko, Taniguchi, Yuko, Ohue, Masayuki, Yano, Masahiko, Sakon, Masato
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 153
container_issue
container_start_page 148
container_title Clinical nutrition ESPEN
container_volume 33
creator Akita, Hirofumi
Takahashi, Hidenori
Asukai, Kei
Tomokuni, Akira
Wada, Hiroshi
Marukawa, Satoko
Yamasaki, Tomoyuki
Yanagimoto, Yoshitomo
Takahashi, Yusuke
Sugimura, Keijiro
Yamamoto, Kazuyoshi
Nishimura, Junichi
Yasui, Masayoshi
Omori, Takeshi
Miyata, Hiroshi
Ochi, Ayami
Kagawa, Ayano
Soh, Yuko
Taniguchi, Yuko
Ohue, Masayuki
Yano, Masahiko
Sakon, Masato
description SummaryBackground & aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC. MethodsWe randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities. ResultsOnly 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity. ConclusionsWe found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network ( http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.
doi_str_mv 10.1016/j.clnesp.2019.06.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2281131802</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405457718303541</els_id><sourcerecordid>2281131802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-890a4988fd6e57727d50c5fddcf4a12ca1cab0ff9a35b775ee7b1164f9f870b13</originalsourceid><addsrcrecordid>eNqFUsluFDEQbSEQiUL-ACEfw6EHu_fmgBRFYZEiEYlwttzlcsZDj23K7kTDJ_JVeJiwiAsnW9Zbyu9VUTwXfCW46F5tVjA7jGFVcTGueLfivH5UHFcNb8um7fvHf92PitMYN5xn3jg2gj8tjmrRtKJqq-Pi-80a2ZLsbNOOecPcksgm652aWVxC8JTsHTJQhOzepjVTjqEFH1VAlxQ6b4EpsJqdXV6fvyzRkYU16j9CTN1mJNMLWXfLAmHpA5I6yK5x60lp69M6v4UdM55YUA4IMwKyrwOk1-yafAwIP0mknPZb-y2bgHeJfJ40LXr3rHhi1Bzx9OE8KT6_vby5eF9efXz34eL8qoRG9KkcRq6acRiM7jCnU_W65dAarcE0SlSgBKiJGzOqup36vkXsJyG6xoxm6Pkk6pPi7KAbyH9dMCa5tRFwnpVDv0RZVYMQtRh4laHNAQp5_khoZCC7VbSTgst9kXIjD0XKfZGSdzIXmWkvHhyWaYv6N-lXbRnw5gDA_M87iyQjWMxRaUs5Jam9_Z_DvwIwW2dBzV9wh3HjF8obEKWQsZJcftov036XxFDzum1E_QMotcxC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2281131802</pqid></control><display><type>article</type><title>The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study</title><source>Alma/SFX Local Collection</source><creator>Akita, Hirofumi ; Takahashi, Hidenori ; Asukai, Kei ; Tomokuni, Akira ; Wada, Hiroshi ; Marukawa, Satoko ; Yamasaki, Tomoyuki ; Yanagimoto, Yoshitomo ; Takahashi, Yusuke ; Sugimura, Keijiro ; Yamamoto, Kazuyoshi ; Nishimura, Junichi ; Yasui, Masayoshi ; Omori, Takeshi ; Miyata, Hiroshi ; Ochi, Ayami ; Kagawa, Ayano ; Soh, Yuko ; Taniguchi, Yuko ; Ohue, Masayuki ; Yano, Masahiko ; Sakon, Masato</creator><creatorcontrib>Akita, Hirofumi ; Takahashi, Hidenori ; Asukai, Kei ; Tomokuni, Akira ; Wada, Hiroshi ; Marukawa, Satoko ; Yamasaki, Tomoyuki ; Yanagimoto, Yoshitomo ; Takahashi, Yusuke ; Sugimura, Keijiro ; Yamamoto, Kazuyoshi ; Nishimura, Junichi ; Yasui, Masayoshi ; Omori, Takeshi ; Miyata, Hiroshi ; Ochi, Ayami ; Kagawa, Ayano ; Soh, Yuko ; Taniguchi, Yuko ; Ohue, Masayuki ; Yano, Masahiko ; Sakon, Masato</creatorcontrib><description>SummaryBackground &amp; aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC. MethodsWe randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities. ResultsOnly 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity. ConclusionsWe found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network ( http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.</description><identifier>ISSN: 2405-4577</identifier><identifier>EISSN: 2405-4577</identifier><identifier>DOI: 10.1016/j.clnesp.2019.06.003</identifier><identifier>PMID: 31451252</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>EPA ; Gastroenterology and Hepatology ; Immunonutrition ; Pancreatic cancer ; Preoperative chemoradiotherapy ; RCT</subject><ispartof>Clinical nutrition ESPEN, 2019-10, Vol.33, p.148-153</ispartof><rights>European Society for Clinical Nutrition and Metabolism</rights><rights>2019 European Society for Clinical Nutrition and Metabolism</rights><rights>Copyright © 2019 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-890a4988fd6e57727d50c5fddcf4a12ca1cab0ff9a35b775ee7b1164f9f870b13</citedby><cites>FETCH-LOGICAL-c417t-890a4988fd6e57727d50c5fddcf4a12ca1cab0ff9a35b775ee7b1164f9f870b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31451252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akita, Hirofumi</creatorcontrib><creatorcontrib>Takahashi, Hidenori</creatorcontrib><creatorcontrib>Asukai, Kei</creatorcontrib><creatorcontrib>Tomokuni, Akira</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Marukawa, Satoko</creatorcontrib><creatorcontrib>Yamasaki, Tomoyuki</creatorcontrib><creatorcontrib>Yanagimoto, Yoshitomo</creatorcontrib><creatorcontrib>Takahashi, Yusuke</creatorcontrib><creatorcontrib>Sugimura, Keijiro</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Nishimura, Junichi</creatorcontrib><creatorcontrib>Yasui, Masayoshi</creatorcontrib><creatorcontrib>Omori, Takeshi</creatorcontrib><creatorcontrib>Miyata, Hiroshi</creatorcontrib><creatorcontrib>Ochi, Ayami</creatorcontrib><creatorcontrib>Kagawa, Ayano</creatorcontrib><creatorcontrib>Soh, Yuko</creatorcontrib><creatorcontrib>Taniguchi, Yuko</creatorcontrib><creatorcontrib>Ohue, Masayuki</creatorcontrib><creatorcontrib>Yano, Masahiko</creatorcontrib><creatorcontrib>Sakon, Masato</creatorcontrib><title>The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study</title><title>Clinical nutrition ESPEN</title><addtitle>Clin Nutr ESPEN</addtitle><description>SummaryBackground &amp; aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC. MethodsWe randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities. ResultsOnly 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity. ConclusionsWe found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network ( http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.</description><subject>EPA</subject><subject>Gastroenterology and Hepatology</subject><subject>Immunonutrition</subject><subject>Pancreatic cancer</subject><subject>Preoperative chemoradiotherapy</subject><subject>RCT</subject><issn>2405-4577</issn><issn>2405-4577</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFUsluFDEQbSEQiUL-ACEfw6EHu_fmgBRFYZEiEYlwttzlcsZDj23K7kTDJ_JVeJiwiAsnW9Zbyu9VUTwXfCW46F5tVjA7jGFVcTGueLfivH5UHFcNb8um7fvHf92PitMYN5xn3jg2gj8tjmrRtKJqq-Pi-80a2ZLsbNOOecPcksgm652aWVxC8JTsHTJQhOzepjVTjqEFH1VAlxQ6b4EpsJqdXV6fvyzRkYU16j9CTN1mJNMLWXfLAmHpA5I6yK5x60lp69M6v4UdM55YUA4IMwKyrwOk1-yafAwIP0mknPZb-y2bgHeJfJ40LXr3rHhi1Bzx9OE8KT6_vby5eF9efXz34eL8qoRG9KkcRq6acRiM7jCnU_W65dAarcE0SlSgBKiJGzOqup36vkXsJyG6xoxm6Pkk6pPi7KAbyH9dMCa5tRFwnpVDv0RZVYMQtRh4laHNAQp5_khoZCC7VbSTgst9kXIjD0XKfZGSdzIXmWkvHhyWaYv6N-lXbRnw5gDA_M87iyQjWMxRaUs5Jam9_Z_DvwIwW2dBzV9wh3HjF8obEKWQsZJcftov036XxFDzum1E_QMotcxC</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Akita, Hirofumi</creator><creator>Takahashi, Hidenori</creator><creator>Asukai, Kei</creator><creator>Tomokuni, Akira</creator><creator>Wada, Hiroshi</creator><creator>Marukawa, Satoko</creator><creator>Yamasaki, Tomoyuki</creator><creator>Yanagimoto, Yoshitomo</creator><creator>Takahashi, Yusuke</creator><creator>Sugimura, Keijiro</creator><creator>Yamamoto, Kazuyoshi</creator><creator>Nishimura, Junichi</creator><creator>Yasui, Masayoshi</creator><creator>Omori, Takeshi</creator><creator>Miyata, Hiroshi</creator><creator>Ochi, Ayami</creator><creator>Kagawa, Ayano</creator><creator>Soh, Yuko</creator><creator>Taniguchi, Yuko</creator><creator>Ohue, Masayuki</creator><creator>Yano, Masahiko</creator><creator>Sakon, Masato</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study</title><author>Akita, Hirofumi ; Takahashi, Hidenori ; Asukai, Kei ; Tomokuni, Akira ; Wada, Hiroshi ; Marukawa, Satoko ; Yamasaki, Tomoyuki ; Yanagimoto, Yoshitomo ; Takahashi, Yusuke ; Sugimura, Keijiro ; Yamamoto, Kazuyoshi ; Nishimura, Junichi ; Yasui, Masayoshi ; Omori, Takeshi ; Miyata, Hiroshi ; Ochi, Ayami ; Kagawa, Ayano ; Soh, Yuko ; Taniguchi, Yuko ; Ohue, Masayuki ; Yano, Masahiko ; Sakon, Masato</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-890a4988fd6e57727d50c5fddcf4a12ca1cab0ff9a35b775ee7b1164f9f870b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>EPA</topic><topic>Gastroenterology and Hepatology</topic><topic>Immunonutrition</topic><topic>Pancreatic cancer</topic><topic>Preoperative chemoradiotherapy</topic><topic>RCT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akita, Hirofumi</creatorcontrib><creatorcontrib>Takahashi, Hidenori</creatorcontrib><creatorcontrib>Asukai, Kei</creatorcontrib><creatorcontrib>Tomokuni, Akira</creatorcontrib><creatorcontrib>Wada, Hiroshi</creatorcontrib><creatorcontrib>Marukawa, Satoko</creatorcontrib><creatorcontrib>Yamasaki, Tomoyuki</creatorcontrib><creatorcontrib>Yanagimoto, Yoshitomo</creatorcontrib><creatorcontrib>Takahashi, Yusuke</creatorcontrib><creatorcontrib>Sugimura, Keijiro</creatorcontrib><creatorcontrib>Yamamoto, Kazuyoshi</creatorcontrib><creatorcontrib>Nishimura, Junichi</creatorcontrib><creatorcontrib>Yasui, Masayoshi</creatorcontrib><creatorcontrib>Omori, Takeshi</creatorcontrib><creatorcontrib>Miyata, Hiroshi</creatorcontrib><creatorcontrib>Ochi, Ayami</creatorcontrib><creatorcontrib>Kagawa, Ayano</creatorcontrib><creatorcontrib>Soh, Yuko</creatorcontrib><creatorcontrib>Taniguchi, Yuko</creatorcontrib><creatorcontrib>Ohue, Masayuki</creatorcontrib><creatorcontrib>Yano, Masahiko</creatorcontrib><creatorcontrib>Sakon, Masato</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nutrition ESPEN</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akita, Hirofumi</au><au>Takahashi, Hidenori</au><au>Asukai, Kei</au><au>Tomokuni, Akira</au><au>Wada, Hiroshi</au><au>Marukawa, Satoko</au><au>Yamasaki, Tomoyuki</au><au>Yanagimoto, Yoshitomo</au><au>Takahashi, Yusuke</au><au>Sugimura, Keijiro</au><au>Yamamoto, Kazuyoshi</au><au>Nishimura, Junichi</au><au>Yasui, Masayoshi</au><au>Omori, Takeshi</au><au>Miyata, Hiroshi</au><au>Ochi, Ayami</au><au>Kagawa, Ayano</au><au>Soh, Yuko</au><au>Taniguchi, Yuko</au><au>Ohue, Masayuki</au><au>Yano, Masahiko</au><au>Sakon, Masato</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study</atitle><jtitle>Clinical nutrition ESPEN</jtitle><addtitle>Clin Nutr ESPEN</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>33</volume><spage>148</spage><epage>153</epage><pages>148-153</pages><issn>2405-4577</issn><eissn>2405-4577</eissn><abstract>SummaryBackground &amp; aimsNeoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer (PC) is potentially associated with various toxicities, which can lead to impaired nutritional status. Eicosapentaenoic acid (EPA) can reduce proinflammatory cytokines and positively influence cancer cachexia syndrome. The aim of this study is to clarify the utility of EPA enriched nutrition support during NACRT for PC. MethodsWe randomly assigned 62 patients with PC that received NACRT to either a nutrition intervention (NI) or a normal diet (ND). Patients in the NI group received 2 bottles/day (550 kcal/day) of an EPA-enriched nutrition supplement during NACRT. The primary endpoints were the before-to-after NACRT ratios (post/pre ratios) of skeletal muscle mass and psoas major muscle area (PMA). The secondary endpoints were the post/pre ratios of other nutritional parameters and treatment-related toxicities. ResultsOnly 14 patients (45.2%) in the NI group consumed more than 50% of the EPA-enriched supplement provided. The post/pre ratio of skeletal muscle mass in the NI group (0.99 ± 0.060) was not significantly different from that of the ND group (0.96 ± 0.079, p = 0.102). However, patients that consumed ≥50% of the EPA-enriched supplement (the good intake group) had significantly higher skeletal muscle mass ratios than patients in the ND group (p = 0.042). The PMA ratio was significantly higher in the NI group (0.96 ± 0.081) than in the ND group (0.89 ± 0.072, p = 0.001). The NI and ND groups were not significantly different in other nutritional parameters or in NACRT-related toxicity. ConclusionsWe found that EPA-enriched intake could potentially improve the nutritional status of patients with PC that received NACRT, but it was difficult for many patients to drink, due to its disagreeable taste. University Hospital Medical Information Network ( http://www.umin.ac.jp), registration number UMIN000033589, https://upload.umin.ac.jp/cgi-bin/ctr_e/ctr_view.cgi?recptno=R000038300.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31451252</pmid><doi>10.1016/j.clnesp.2019.06.003</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2405-4577
ispartof Clinical nutrition ESPEN, 2019-10, Vol.33, p.148-153
issn 2405-4577
2405-4577
language eng
recordid cdi_proquest_miscellaneous_2281131802
source Alma/SFX Local Collection
subjects EPA
Gastroenterology and Hepatology
Immunonutrition
Pancreatic cancer
Preoperative chemoradiotherapy
RCT
title The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A28%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20utility%20of%20nutritional%20supportive%20care%20with%20an%20eicosapentaenoic%20acid%20(EPA)-enriched%20nutrition%20agent%20during%20pre-operative%20chemoradiotherapy%20for%20pancreatic%20cancer:%20Prospective%20randomized%20control%20study&rft.jtitle=Clinical%20nutrition%20ESPEN&rft.au=Akita,%20Hirofumi&rft.date=2019-10-01&rft.volume=33&rft.spage=148&rft.epage=153&rft.pages=148-153&rft.issn=2405-4577&rft.eissn=2405-4577&rft_id=info:doi/10.1016/j.clnesp.2019.06.003&rft_dat=%3Cproquest_cross%3E2281131802%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2281131802&rft_id=info:pmid/31451252&rft_els_id=S2405457718303541&rfr_iscdi=true